The global hydroxyzine market value is estimated to total USD 829.9 million in 2024 and US$ 1430 million by 2034. Global demand is projected to increase at a CAGR of 5.6% throughout the forecast period, fueled by the increasing prevalence of allergic diseases and anxiety disorders.
Tablets remain the popular dosage form in the market, accounting for a dominant value share of 38% in 2023. This is attributable to the convenience, ease of use, and longer shelf life of tablets than other forms.
Request A Report Sample: https://www.futuremarketinsights.com/reports/sample/rep-gb-19602
Hydroxyzine has become a widely used antihistamine medication for treating itchiness, nausea, anxiety, and insomnia. Thus, increasing the incidence of these health conditions is anticipated to boost the growth of the hydroxyzine industry during the assessment period.
According to the European Academy of Allergy and Clinical Immunology (EAACI), allergic diseases affect over one billion people worldwide. Further, emerging trends estimate the total number of people suffering from allergic diseases to reach around 4 billion by 2050. This will likely uplift the demand for hydroxyzine.
Another prominent factor influencing sales growth is the growing geriatric population, coupled with rising mental health awareness. As the incidence of anxiety and related conditions continues to increase, the need for medications like hydroxyzine is set to grow steadily for managing them.
Leading companies are constantly innovating to discover new therapeutic applications of hydroxyzine as well as improve its efficacy. This will further boost market growth during the next ten years.
Key Takeaways from the Market Report:
- The global market is projected to reach USD 1430 million by 2034, registering a 5.6% CAGR.
- Based on dosage form, the tablets segment is set to record a CAGR of 4% through 2034.
- By indication type, the atopic contact dermatitis segment dominates the industry with a share of 42% in 2023.
- China is estimated to record a CAGR of 3% between 2024 and 2034.
- Sales in the United States are predicted to total USD 258.2 million by 2034.
“Escalating demand for antihistamines due to increasing incidence of allergic disease is anticipated to boost sales growth during the next decade,” says a lead Future Market Insights (FMI) analyst.
Customization with Our Report: https://www.futuremarketinsights.com/customization-available/rep-gb-19602
Who is Winning?
The global industry is becoming highly competitive, with top players like Teva Pharmaceuticals, Pfizer, Inc., and GSK, plc accounting for significant shares. Leading players are heavily investing in research and development to enhance hydroxyzine formulations, explore new indications for the drug, and develop new delivery methods.
Companies are also implementing strategies like mergers, partnerships, acquisitions, and distribution agreements to stay ahead of the competition. Several players are also establishing new drug production facilities in attractive regions to expand their footprint and meet the growing demand for antihistamine medications.
Industry Update-
- In April 2023, Israel-based Teva Pharmaceutical established a new research and development facility in Hungary to speed up production and get medicines to patients faster.
Leading Hydroxyzine Brands:
- Teva Pharmaceuticals
- Pfizer, Inc.
- GSK, plc
- Alliance Pharma PLC
- Piramal Group (Piramal Healthcare UK Limited)
- Impax Laboratories, Inc
- Novartis AG
- Shanghai Ruizheng Chemical Technology Co., Ltd
- N&R Industries
Get Full Report Now: https://www.futuremarketinsights.com/checkout/19602
Key Segments of the Market Report:
By Dosage Form:
In terms of dosage form, the industry has been categorized into tablets, capsules, injections, and syrup.
By Indication Type:
Based on indication type, the industry is segmented into histamine-mediated pruritus, urticaria, and atopic contact dermatitis.
By Region:
Industry analysis has been carried out in key countries of North America, Latin America, Europe, East Asia, South Asia, Oceania, and the Middle East and Africa.
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 400 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube